Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21386280 | 0.82 | SORT1 (0.41) | L3MBTL1SORT1KDM4EMAPTGAA | |
| SCHEMBL28941022 | 0.80 | SORT1 (0.54) | SORT1KDM4EMAPTGAANPC1 | |
| SCHEMBL17857141 | 0.80 | L3MBTL1 (0.47) | L3MBTL1KDM4EMAPTADORA1POLB | |
| SCHEMBL15017984 | 0.80 | L3MBTL1 (0.47) | L3MBTL1KDM4EMAPTADORA1POLB | |
| SCHEMBL5591663 | 0.80 | L3MBTL1 (0.47) | L3MBTL1MAPTGAAADORA1POLB | |
| SCHEMBL13904227 | 0.80 | L3MBTL1 (0.47) | L3MBTL1KDM4EMAPTADORA1POLB | |
| SCHEMBL3923269 | 0.79 | L3MBTL1 (0.46) | L3MBTL1KDM4EMAPTADORA1ALDH1A1 | |
| SCHEMBL14009931 | 0.79 | GLS (0.50) | L3MBTL1SORT1KDM4EMAPTGAA | |
| SCHEMBL5598367 | 0.76 | L3MBTL1 (0.43) | L3MBTL1KDM4EMAPTADORA1POLB | |
| SCHEMBL15017866 | 0.75 | GLS (0.43) | L3MBTL1MAPTADORA1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233839-B1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-25 | — | — | EP | disclosed |
| EP-3233862-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-03 | — | — | EP | disclosed |
| US-20170073334-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-03-16 | — | — | US | disclosed |
| CN-101142217-B | Imidazopyridazine compounds | LILLY CO ELI | 2010-12-08 | — | — | CN | disclosed |
| US-7612067-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-11-03 | — | — | US | disclosed |
| US-7557103-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1869049-B1 | IMIDAZOPYRIDAZINE COMPOUNDS | LILLY CO ELI (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20080153828-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-06-26 | — | — | US | disclosed |
| US-20080113978-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| CN-101142217-A | Imidazopyridazine compounds | LILLY CO ELI (US) | 2008-03-12 | — | — | CN | disclosed |
| EP-1879896-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1869049-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006107784-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006102194-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073334-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | PRKACA, PRKDC, PRKACB | L3MBTL1 2514/4885SORT1 2684/4885KDM4E 1978/4885 |
| US-20080153828-A1 | Imidazopyridazine Compounds | CRHR1, CRH, CRHR2 | L3MBTL1 4787/4885SORT1 3435/4885KDM4E 4385/4885 |
| US-20080113978-A1 | Imidazopyridazine Compounds | CRHR1, CRH, CRHR2 | L3MBTL1 4790/4885SORT1 3409/4885KDM4E 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.